Capricor Therapeutics Incorporated (NASDAQ:CAPR) Has Increase in Shorts

September 17, 2017 - By Henry Gaston

 Capricor Therapeutics Incorporated (NASDAQ:CAPR) Has Increase in Shorts

Investors sentiment decreased to 1 in 2016 Q4. Its down 0.33, from 1.33 in 2016Q3. It dropped, as 4 investors sold Capricor Therapeutics Inc shares while 2 reduced holdings. 2 funds opened positions while 4 raised stakes. 764,994 shares or 9.01% less from 840,701 shares in 2016Q3 were reported.
Cordasco Net holds 3,100 shares or 0.01% of its portfolio. Morgan Stanley invested in 0% or 39,000 shares. Susquehanna Gp Ltd Liability Partnership has 0% invested in Capricor Therapeutics Inc (NASDAQ:CAPR). Blackrock Fund holds 0% or 16,598 shares. Blackrock Mngmt Limited Liability invested in 410 shares or 0% of the stock. Geode Cap Management Ltd Liability Co stated it has 43,929 shares. Vanguard Grp invested in 0% or 50,790 shares. Blackrock Lc owns 1,665 shares or 0% of their US portfolio. Brown Advisory has 0% invested in Capricor Therapeutics Inc (NASDAQ:CAPR) for 71,065 shares. Sabby Llc reported 372,046 shares stake. Bancorp Of America De holds 0% or 3,000 shares. Perceptive Ltd Liability holds 0% of its portfolio in Capricor Therapeutics Inc (NASDAQ:CAPR) for 4,000 shares. Architects Incorporated reported 2,000 shares. Granite Point Capital Mgmt Ltd Partnership accumulated 0.14% or 67,500 shares. Goldman Sachs Group has 75,561 shares.

Since May 9, 2017, it had 3 insider buys, and 0 insider sales for $3.66 million activity. The insider CEDARS SINAI MEDICAL CENTER bought 1.15 million shares worth $3.55 million. On Tuesday, May 9 the insider Manzo Louis bought $31,000. Musket David B bought $77,500 worth of stock or 25,000 shares.

The stock of Capricor Therapeutics Incorporated (NASDAQ:CAPR) registered an increase of 16.72% in short interest. CAPR’s total short interest was 916,400 shares in September as published by FINRA. Its up 16.72% from 785,100 shares, reported previously. With 175,700 shares average volume, it will take short sellers 5 days to cover their CAPR’s short positions. The short interest to Capricor Therapeutics Incorporated’s float is 8.88%.

The stock increased 3.09% or $0.03 on September 15, reaching $1. About 1.08 million shares traded or 265.46% up from the average. Capricor Therapeutics Inc (NASDAQ:CAPR) has declined 72.31% since September 17, 2016 and is downtrending. It has underperformed by 89.01% the S&P500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm focused on the discovery, development and commercialization of therapeutics. The company has market cap of $23.50 million. The Firm focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. It currently has negative earnings. The Company’s product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction , while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure.

Capricor Therapeutics Inc (NASDAQ:CAPR) Ratings Coverage

Among 2 analysts covering Capricor Therapeutics (NASDAQ:CAPR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Capricor Therapeutics had 4 analyst reports since June 15, 2016 according to SRatingsIntel. The rating was reinitiated by H.C. Wainwright with “Buy” on Wednesday, July 6. The stock of Capricor Therapeutics Inc (NASDAQ:CAPR) has “Buy” rating given on Wednesday, June 15 by Roth Capital. H.C. Wainwright maintained it with “Buy” rating and $6.5 target in Friday, September 15 report. The firm earned “Buy” rating on Monday, July 10 by H.C. Wainwright.

More notable recent Capricor Therapeutics Inc (NASDAQ:CAPR) news were published by: which released: “Capricor Therapeutics Reports Fourth Quarter and Full Year 2016 Financial …” on March 15, 2017, also with their article: “Capricor Therapeutics’ (CAPR) CEO Dr. Linda Marbán on Q2 2017 Results …” published on August 11, 2017, published: “Capricor Therapeutics Completes Enrollment in Phase II ALLSTAR Clinical Trial” on October 05, 2016. More interesting news about Capricor Therapeutics Inc (NASDAQ:CAPR) were released by: and their article: “Capricor Therapeutics Stock Surging on Positive Muscular Dystrophy Trial Results” published on April 25, 2017 as well as‘s news article titled: “Capricor Trial Failure In Heart Disease Might Offer Another Opportunity” with publication date: May 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: